The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 3, 1996, Pages 283-294

  Vachharajani, Nimish N ^a   Shyu, Wen Chyi ^b   Garnett, William R ^b   Morgenthien, Elizabeth A ^b   Barbhaiya, Rashmi H ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUTORPHANOL; DRUG METABOLITE; INDOCYANINE GREEN; PHENAZONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER FAILURE; LIVER FUNCTION; MALE; NAUSEA; NEUROTOXICITY; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; STEADY STATE; VERTIGO;

ADMINISTRATION, INTRANASAL; ADULT; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPYRINE; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BUTORPHANOL; COLORING AGENTS; FEMALE; HUMANS; INDOCYANINE GREEN; INJECTIONS, INTRAVENOUS; LIVER CIRCULATION; LIVER DISEASES; MALE; MIDDLE AGED; REFERENCE VALUES;

EID: 0029810117     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90055-7     Document Type: Article

References (18)

1. Gaver RC, Vasiljev M, Wong H, Monkovic I, Swigor JE, Van Harken DR, et al. Disposition of parenteral butorphanol in man. Drug Metab Dispos 1980;8:230-5.
2. Shyu WC, Pittman KA, Robinson DS, Barbhaiya RH. The absolute bioavailability and pharmacokinetics of transnasal butorphanol in patients experiencing rhinitis. Eur J Clin Pharmacol 1993;45:559-62.
3. Shyu WC, Morgenthien EA, Pittman KA, Barbhaiya RH. The effects of age and sex on the systemic availability and pharmacokinetics of transnasal butorphanol. Eur J Clin Pharmacol 1994;47:57-60.
4. Shyu WC, Pittman KA, Robinson DS, Barbhaiya RH. Multiple dose phase I study of transnasal butorphanol. Clin Pharmacol Ther 1993;54:34-41.
5. Pittman KA, Smyth RD, Mayol RF. Serum levels of butorphanol by radioimmunoassay. J Pharm Sci 1980; 69:160-3.
6. Willey TA, Duncan GF, Tay LK, Pittman KA, Farmen RH. High-performance liquid chromatographic method for the quantitative determination of butorphanol, hydroxybutorphanol and norbutorphanol in human urine using fluorescence detection. J Chromatogr 1994;652:171-8.
7. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982:409-17.
8. Riegelman S, Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1980;8:509-34.
9. Branch RA, Shand DG. Propranolol disposition in chronic liver disease: a physiological approach. Clin Pharmacokinet 1976;1:264-79.
10. Rowland M, Blaschke TF, Meffin PJ, Williams RL. Pharmacokinetics in disease states modifying hepatic and metabolic function. In: Benet LZ, editor. The effect of disease states on drug pharmacokinetics. Washington: American Pharmaceutical Association, 1976:53-76.
11. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975; 18:377-90.
12. McLean A, du Souich P, Gibaldi M. Noninvasive kinetic approach to the estimation of total hepatic blood flow and shunting in chronic liver disease - a hypothesis. Clin Pharmacol Ther 1979;25:161-6.
13. St Peter JV, Awni WM. Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites. Clin Pharmacokinet 1991;20:50-65.
14. Branch RA, Herbert CM, Read AE. Determinants of serum antipyrine half-lives in patients with liver disease. Gut 1973;14:569-73.
15. Conover WJ, Iman RL. Rank transformations as a bridge between parametric and nonparametric statistics. Am Statistician 1981;35:124-33.
16. Box GEP, Cox DR. Analysis of transformations. J R Stat Soc Ser B 1964;26:211-52.
17. Branch RA, James JA, Read AE. The clearance of antipyrine and indocyanine green in normal subjects and patients with chronic liver disease. Clin Pharmacol Ther 1976;20:81-9.
18. Pieniaszek HJ, Davidson AF, McEntegart CM, Quon CY, Sampliner RE, Mayerson M. The effect of hepatic disease on the disposition of moricizine in humans. Biopharm Drug Dispos 1994;15:243-52.